Bio-Rad Laboratories, Inc. (BIO) financial statements and ratios from SEC XBRL: revenue $2.58B (TTM), net margin 29.4%, revenue growth 0.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $2.58B |
| Net Margin | 29.4% |
| Revenue Growth (YoY) | 0.7% |
| EPS Growth (YoY) | -142.6% |
| FCF Growth (YoY) | 29.4% |
| EV / EBITDA | 52.2 |
| Price / Book | 1.48 |
| Price / Sales | 4.09 |
| FCF Yield | 5.9% |
| DCF Value (model) | $199.34 |
| DCF Upside vs Price | -47.1% |
| Altman Z-Score | 3.59 (safe) |
| Piotroski F-Score | 5/9 |
| Sector P/E (Technology) | 33.9 |
BIO overview · BIO earnings · BIO KPIs · BIO investor relations · BIO ownership · BIO peers · BIO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.